The Lyon-based company ACS BIOTECH, specialized in cartilage repair, is launching a new crowdfunding operation on the HAPPY CAPITAL platform with the aim of raising $665,000 (€600,000) from the general public. The funds will enable the company to continue the clinical development of its innovative solution for the treatment of osteoarthritis.
Breaking news from the biotech, clinical research, and pharmaceutical industries. The Born2Invest app deals with business headlines, emerging biotech companies, and other biotechnology articles on biotech industry leaders.
Good news for the treatment of osteoarthritis
This degenerative and painful joint disease affects more than 230 million patients worldwide, including more than 10 million in France. These figures are constantly increasing due to societal factors such as the evolution of obesity and the aging population. Anatomically, osteoarthritis results in the destruction of cartilage in the joints (knee, hip, etc.) causing severe pain and a significant reduction in mobility. Cartilage is a non-innervated and non-vascularised tissue that cannot regenerate spontaneously. So far, there is no effective cartilage repair solution to permanently combat tissue degeneration and eliminate pain known to date.
The patented ACS BIOTECH solution is a unique product for the repair of cartilage lesions by minimally invasive surgery in only one injection. The articular cartilage gel ready for implantation will allow a definitive repair. This revolution made possible by innovative biomaterials has been developed as part of a research project with the CNRS. The marketing of the first injectable kits is planned within 3 years.
Pascale Hazot, the head of the company, Doctor in Materials Chemistry and graduate of an International MBA at EM Lyon, has surrounded herself with a multidisciplinary team. The team includes experts in biomaterials, cell and molecular biology as well as regulatory affairs. ACS BIOTECH, created in 2013, also relies on an internationally renowned scientific committee (CNRS, Hospitals and Clinics). The startup is located at the Lyon Biopôle Innovation Center, a world-class healthcare competitiveness cluster.
Initially incubated at EM LYON, the company also benefits from the support and guidance of BPI France, BPAURA, CIC, the Auvergne Rhône Alpes Region and the European Commission within the framework of the EIT Health and Eurostars programs.
ACS Biotech has also been rewarded with numerous prizes such as ‘Lab Meeting’ at the ‘Innovation highlights Brief Eco 2019’, ‘Entrepreneur of the year 2018’ at the Alumni Makers Awards of the EM LYON, ‘Economy’s favorite 2017’ by the VOXX, ‘The Bucket of Excellence’ in 2017 for its cartilage repair project in the H2020 program of the European Commission and ‘Startup Connexion’ of the CNRS in 2016.
Crowdfunding to finance its development
ACS BIOTECH chooses the participative economy to reaffirm its values and allow investors to give meaning to their savings while financing the real economy. The company is partnering with the HAPPY CAPITAL platform to raise $332,000 (€300,000) until March and reach $665,000 (€600,000) before June. The fundraising campaign has already raised more than $55,000 (€50,000) in just a few days.
The HAPPY CAPITAL platform invests alongside private individuals, convinced by the project’s ability to revolutionize the medical management of osteoarthritis.
ACS BIOTECH is a biotechnology company specialized in the design of innovative matrices of natural polymers for the development of regenerative medicine solutions. ACS has developed an innovative injectable cell therapy solution for cartilage repair based on a unique 3D chitosan hydrogel matrix to offer a new generation of chondrocyte grafting. The company exploits the properties of chitosan (biocompatible, bioresorbable, good cell adhesion) for perfect control of the cells before implantation.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in caducee.net, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Why is the stock market up?
A global pandemic. The President impeached. Raging wildfires across the west coast. Riots throughout major cities. The Olympics cancelled. The...
The biotech sector in Bavaria has strongly developed over the last years
Bavaria has been able to establish itself as a location for biotechnology and innovation in recent decades. However, at an...
How the coronavirus pandemic impacted the German Fintech sector
The coronavirus pandemic has clearly affected the Fintech sector in Germany. However, some of the companies that are currently struggling,...
What’s the problem with the Dow Jones? Maybe it’s overvalued
So far, the Dow Jones has yet to exceed the high of its current advance on August 3rd. Who knows...
Fruitbox Africa: Frankfurt investor and Siemens to create jobs in Ethiopia
The Frankfurt investor Lutz Hartmann and the technology giant Siemens want to invest in Ethiopia. Creating jobs, training young people,...
Featured6 days ago
Qonto registered over €900 million value of transactions on Italian current accounts
Cannabis7 days ago
Cannabis light company to sponsor Italian soccer league teams
Crypto7 days ago
Why are Ethereum fees higher than Bitcoin ones?
Business7 days ago
XRApplied sitting pretty on the precipice of the XR boom